Sarepta Announces Biologics License Application (BLA) Accepted For Filing by the FDA for SRP-9001
PPMD is thrilled to learn that the FDA has accepted for filing and granted priority review for the Biologics License Application (BLA) for Sarepta’s gene therapy product, SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant…Learn More